Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation

  • Daniele Mannina
  • Nico Gagelmann
  • Anita Badbaran
  • Markus Ditschkowski
  • Rashit Bogdanov
  • Marie Robin
  • Bruno Cassinat
  • Michael Heuser
  • Rabia Shahswar
  • Felicitas Thol
  • Dietrich Beelen
  • Nicolaus Kröger

Abstract

INTRODUCTION: Primary and post-ET/PV myelofibrosis are myeloproliferative neoplasms harboring in most cases driving mutations in JAK2, CALR or MPL, and a variable number of additional mutations in other genes. Molecular analysis represents a powerful tool to guide prognosis and clinical management. Only about 10% of patients with myelofibrosis harbor alterations in MPL gene. No data are available about the transplantation outcome in the specific MPL-mutated group.

PATIENTS: We collected the data of 18 myelofibrosis patients(primary: 14; post-ET: 4) transplanted in 4 EBMT centers (Hamburg, Paris, Essen, and Hannover) between 2005 and 2016.

RESULTS: Before the transplant, we explored the molecular profile by NGS and reported the frequency of mutations occurring in a panel of genes including JAK2, MPL, CALR, U2AF1, SRSF2, SF3B1, ASXL1, IDH1, IDH2, CBL, DNMT3A, TET2, EZH2, TP53, IKZF1, NRAS, KRAS, FLT3, SH2B3, and RUNX1. The 1-year transplant-related mortality was 16.5%, 5-years overall survival and 5-y relapse-free survival 83.5%. The only relapse occurred in a patient who harbored mutations in both ASXL1 and EZH2 genes.

CONCLUSION: These retrospective data suggest that MPL-mutated myelofibrosis patients have a favorable outcome after allogeneic transplantation with very low rate of disease relapse (5.5%) in comparison with the available historical controls regarding myelofibrosis in all.

Bibliografische Daten

OriginalspracheEnglisch
ISSN0902-4441
DOIs
StatusVeröffentlicht - 12.2019

Anmerkungen des Dekanats

© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

PubMed 31446640